Loading
A phase 2 trial of FAP-2286, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC is a phase 2 interventional study registered as NCT06894511 by Novartis Pharmaceuticals, with 7 participants enrolled, started 2025-09-11 and due to reach its primary completion in 2026-10-15. Interventions recorded: AAA617, ARPI: Abiraterone, ARPI: Enzalutamide. Conditions listed: Metastatic Castration Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Shares Lutetium-177 vipivotide tetraxetan, Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), Novartis, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Lutetium-177 vipivotide tetraxetan, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.